geographic atrophy

Astellas’ Izervay reduces GA lesion growth in Phase III trial
Astellas’ Izervay reduces GA lesion growth in Phase III trial
Clinical Trials Arena
Astellas
Izervay
geographic atrophy
age-related macular degeneration
clinical trials
Flag link:
Iveric Bio Announces Positive 24-Month Topline Results from Phase 3 Study of Izervay for Geographic Atrophy
Iveric Bio Announces Positive 24-Month Topline Results from Phase 3 Study of Izervay for Geographic Atrophy
PR Newswire
Astellas
clinical trials
Izervay
geographic atrophy
Flag link:
Novartis Drops Eye Disease Gene Therapy from $800M Gyroscope Acquisition
Novartis Drops Eye Disease Gene Therapy from $800M Gyroscope Acquisition
BioSpace
Novartis
GT005
gene therapy
geographic atrophy
Gyroscope Therapeutics
Flag link:
Iveric drug approved for type of vision loss as rival’s safety draws scrutiny
Iveric drug approved for type of vision loss as rival’s safety draws scrutiny
BioPharma Dive
Iveric Bio
geographic atrophy
FDA
Izervay
Astellas
Flag link:
Annexon finds more silver linings in failed eye disease trial ahead of talks with FDA
Annexon finds more silver linings in failed eye disease trial ahead of talks with FDA
Fierce Biotech
Annexon
clinical trials
geographic atrophy
ANX007
Flag link:
Go or no go? Biogen and Astellas head towards key PDUFAs
Go or no go? Biogen and Astellas head towards key PDUFAs
EP Vantage
FDA
Astellas
Zimura
Biogen
SAGE Therapeutics
zuranolone
major depressive disorder
postpartum depression
geographic atrophy
Flag link:
Experts flag eye inflammation reports tied to Apellis' geographic atrophy med Syfovre
Experts flag eye inflammation reports tied to Apellis' geographic atrophy med Syfovre
Fierce Pharma
Apellis Pharmaceuticals
Syfovre
geographic atrophy
side effects
Flag link:
Annexon reports topline results from Phase II trial of geographic atrophy therapy
Annexon reports topline results from Phase II trial of geographic atrophy therapy
Clinical Trials Arena
Annexon
clinical trials
ANX007
vision loss
geographic atrophy
Flag link:
Apellis reports strong start for new vision loss drug
Apellis reports strong start for new vision loss drug
BioPharma Dive
Apellis Pharmaceuticals
Syfovre
geographic atrophy
Flag link:
Playing catch-up, Boehringer taps RetinAI for AI boost to eye disease R&D
Playing catch-up, Boehringer taps RetinAI for AI boost to eye disease R&D
Fierce Biotech
Boehringer Ingelheim
RetinAI
artificial intelligence
geographic atrophy
R&D
Flag link:
FDA accepts Iveric Bio's NDA, grants priority review for GA drug
FDA accepts Iveric Bio's NDA, grants priority review for GA drug
Endpoints
Iveric Bio
FDA
geographic atrophy
Apellis Pharmaceuticals
avacincaptad pegol
Flag link:
FDA Approves Apellis' Syfovre as First Treatment for Geographic Atrophy
FDA Approves Apellis' Syfovre as First Treatment for Geographic Atrophy
BioSpace
Apellis Pharmaceuticals
Syfovre
pegcetacoplan
FDA
geographic atrophy
Flag link:
Merck & Co. bails on NGM eye disease collab in wake of phase 2 fail
Merck & Co. bails on NGM eye disease collab in wake of phase 2 fail
Fierce Biotech
Merck
NGM Biopharmaceuticals
clinical trials
eye disease
NGM621
geographic atrophy
Flag link:
Genentech starts phase 2 trial to optimize delivery of eye disease cell therapy
Genentech starts phase 2 trial to optimize delivery of eye disease cell therapy
Fierce Pharma
Genentech
geographic atrophy
clinical trials
OpRegen
cell therapy
Flag link:
Apellis Pharmaceuticals Surges On New Review Date For Eye-Disease Treatment
Apellis Pharmaceuticals Surges On New Review Date For Eye-Disease Treatment
Investors Business Daily
Apellis Pharmaceuticals
pegcetacoplan
eye disease
geographic atrophy
Flag link:
Roche Scraps Mid-Phase Programs in Hepatitis B, Geographic Atrophy
Roche Scraps Mid-Phase Programs in Hepatitis B, Geographic Atrophy
BioSpace
Roche
hepatitis B
geographic atrophy
Flag link:
Iveric hits again in pivotal eye disease program, keeping it on Apellis' tail in race to market
Iveric hits again in pivotal eye disease program, keeping it on Apellis' tail in race to market
Fierce Biotech
Iveric Bio
Apellis Pharmaceuticals
clinical trials
FDA
dry eye disease
geographic atrophy
Flag link:
Apellis Surges By Double Digits As FDA Mulls Its Eye-Disease Treatment
Apellis Surges By Double Digits As FDA Mulls Its Eye-Disease Treatment
Investors Business Daily
Apellis Pharmaceuticals
geographic atrophy
FDA
pegcetacoplan
Flag link:
Apellis plots pegcetacoplan FDA filing in blockbuster GA use after revealing 18-month data
Apellis plots pegcetacoplan FDA filing in blockbuster GA use after revealing 18-month data
Fierce Pharma
Apellis
pegcetacoplan
geographic atrophy
FDA
Flag link:
Apellis eye drug succeeds in one key study, but falls short in its twin
Apellis eye drug succeeds in one key study, but falls short in its twin
BioPharma Dive
Apellis Pharmaceuticals
FDA
pegcetacoplan
geographic atrophy
Flag link:

Pages